Live price temporarily unavailable.
Corbus Pharmaceuticals Holdings (CRBP) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.91M | $2.44M | $4.82M | $36.1M | $3.94M | $881.7K | $0 | — | — | — |
| Growth (year over year) | +194.8% | +27.7% | +97.6% | +649.5% | −89.1% | −77.6% | −100.0% | — | — | — |
| Operating income | −$20.0M | −$32.6M | −$56.7M | −$77.1M | −$122.8M | −$56.0M | −$39.8M | −$45.1M | −$48.7M | −$85.3M |
| Operating margin | −1045.6% | −1334.4% | −1176.8% | −213.3% | −3119.2% | −6350.1% | — | — | — | — |
| Net income | −$20.0M | −$32.4M | −$55.7M | −$71.5M | −$111.3M | −$45.6M | −$42.3M | −$44.6M | −$40.2M | −$78.5M |
| Net margin | −1046.3% | −1328.6% | −1154.5% | −197.7% | −2826.1% | −5176.4% | — | — | — | — |
| EPS (diluted) | −$441.00 | −$585.00 | −$882.00 | −$1008.00 | −$1278.00 | −$11.15 | −$10.15 | −$10.31 | −$3.68 | −$5.90 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.0M | $62.5M | $41.7M | $31.7M | $85.4M | $25.0M | $17.0M | $13.7M | $17.2M | $28.5M |
| Total assets | $17.9M | $67.0M | $47.0M | $49.1M | $102.3M | $107.7M | $66.3M | $28.3M | $155.9M | $168.2M |
| Total liabilities | $8.97M | $9.19M | $19.5M | $43.0M | $57.0M | $38.6M | $33.3M | $35.2M | $13.5M | $20.7M |
| Long-term debt | — | — | — | — | $18.0M | $15.6M | $16.0M | $0 | — | — |
| Shareholders' equity | $8.92M | $57.8M | $27.5M | $6.16M | $45.3M | $69.1M | $33.0M | −$6.91M | $142.4M | $147.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$13.6M | −$27.8M | −$30.1M | −$45.7M | −$99.7M | −$48.2M | −$37.5M | −$36.1M | −$41.8M | −$64.5M |
| Capital expenditure | $353.0K | $707.4K | $2.30M | $2.74M | $484.5K | $54.2K | $13.4K | $0 | $0 | $7.00K |
| Free cash flow | −$13.9M | −$28.5M | −$32.4M | −$48.5M | −$100.2M | −$48.2M | −$37.6M | −$36.1M | −$41.8M | −$64.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$15.5M | −$12.6M | −$19.8M | −$19.2M | −$24.4M | −$22.0M | −$24.3M | −$36.2M |
| Net income | −$13.8M | −$9.53M | −$17.0M | −$17.7M | −$23.3M | −$20.6M | −$23.0M | −$35.0M |
| EPS (diluted) | −$1.15 | −$0.80 | −$1.39 | −$1.44 | −$1.90 | −$1.17 | −$1.23 | −$1.81 |
| Balance sheet | ||||||||
| Cash and equivalents | $19.4M | $17.2M | $18.9M | $20.0M | $27.0M | $28.5M | $25.7M | $23.4M |
| Total assets | $164.2M | $155.9M | $139.9M | $125.1M | $109.5M | $168.2M | $144.5M | $127.0M |
| Total liabilities | $13.7M | $13.5M | $12.8M | $14.1M | $17.4M | $20.7M | $18.1M | $24.7M |
| Shareholders' equity | $150.5M | $142.4M | $127.1M | $111.0M | $92.1M | $147.5M | $126.3M | $102.2M |
| Cash flow | ||||||||
| Operating cash flow | −$13.9M | −$10.9M | −$16.4M | −$16.6M | −$15.6M | −$15.9M | −$25.6M | −$29.6M |
| Capital expenditure | — | — | $0 | $0 | — | — | $6.00K | $6.00K |
| Free cash flow | — | — | −$16.4M | −$16.6M | — | — | −$25.6M | −$29.6M |
From Corbus Pharmaceuticals Holdings's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Corbus Pharmaceuticals Holdings in our feed yet.